SGCB and chronic thromboembolic pulmonary hypertension: Riociguat, an sGC stimulator, has FDA approval for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (37), and more recently the sGC stimulator vericiguat was approved for chronic heart failure (38).